Avexa AGM 2015
Avexa
This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Avexa to be materially different from the statements in this presentation.
Actual results could differ materially depending on factors such as the availability of resources, the results of pre-clinical proof-of-concept studies, the timing and effects of regulatory actions, the strength of competition and the effectiveness of patent protection.
Additional information regarding risks and uncertainties is
available from Avexa on request.
TALI - exciting new opportunity
TALI Health Acquisition
TALI technology is a breakthrough in the improvement and measuring
of attention in children
An initial focus on developmental delay such as autism.
TALI has been proven to improve attention and school outcomes in a clinical trial
For the first time TALI provides a repeatable measure to replace the
existing, often subjective, measures.
Monash University has developed TALI technology in conjunction with Grey innovation and Torus games
distributed by |